Supplemental material
Emerging Microbes & Infections
Volume 12, 2023 - Issue 1
Open access
2,938
Views
1
CrossRef citations to date
0
Altmetric
Influenza infections
Development of an mRNA vaccine against a panel of heterologous H1N1 seasonal influenza viruses using a consensus hemagglutinin sequence
Ning Maa National Engineering Technology Research Center for Combined Vaccines, Wuhan, People’s Republic of China;b The Second Laboratory of Viral Vaccine Research, Wuhan Institute of Biological Products Co. Ltd., Wuhan, People’s Republic of ChinaView further author information
, Zhi-Wu Xiaa National Engineering Technology Research Center for Combined Vaccines, Wuhan, People’s Republic of China;c School of Animal Science and Technology, School of Animal Medicine, Huazhong Agricultural University, Wuhan, People’s Republic of ChinaView further author information
, Zhe-Gang Zhanga National Engineering Technology Research Center for Combined Vaccines, Wuhan, People’s Republic of China;b The Second Laboratory of Viral Vaccine Research, Wuhan Institute of Biological Products Co. Ltd., Wuhan, People’s Republic of ChinaView further author information
, Xuan-Xuan Niana National Engineering Technology Research Center for Combined Vaccines, Wuhan, People’s Republic of China;b The Second Laboratory of Viral Vaccine Research, Wuhan Institute of Biological Products Co. Ltd., Wuhan, People’s Republic of ChinaView further author information
, Xue-Dan Lia National Engineering Technology Research Center for Combined Vaccines, Wuhan, People’s Republic of China;b The Second Laboratory of Viral Vaccine Research, Wuhan Institute of Biological Products Co. Ltd., Wuhan, People’s Republic of ChinaView further author information
, Zheng Gonga National Engineering Technology Research Center for Combined Vaccines, Wuhan, People’s Republic of China;b The Second Laboratory of Viral Vaccine Research, Wuhan Institute of Biological Products Co. Ltd., Wuhan, People’s Republic of ChinaView further author information
, Guo-Mei Zhanga National Engineering Technology Research Center for Combined Vaccines, Wuhan, People’s Republic of China;b The Second Laboratory of Viral Vaccine Research, Wuhan Institute of Biological Products Co. Ltd., Wuhan, People’s Republic of ChinaView further author information
, Yang Lea National Engineering Technology Research Center for Combined Vaccines, Wuhan, People’s Republic of China;b The Second Laboratory of Viral Vaccine Research, Wuhan Institute of Biological Products Co. Ltd., Wuhan, People’s Republic of ChinaView further author information
, Rong Zhoua National Engineering Technology Research Center for Combined Vaccines, Wuhan, People’s Republic of China;b The Second Laboratory of Viral Vaccine Research, Wuhan Institute of Biological Products Co. Ltd., Wuhan, People’s Republic of ChinaView further author information
, Jia-You Zhanga National Engineering Technology Research Center for Combined Vaccines, Wuhan, People’s Republic of China;b The Second Laboratory of Viral Vaccine Research, Wuhan Institute of Biological Products Co. Ltd., Wuhan, People’s Republic of ChinaCorrespondence[email protected]
View further author information
& View further author information
Xiao-Ming Yanga National Engineering Technology Research Center for Combined Vaccines, Wuhan, People’s Republic of China;d China National Biotec Group Company Limited, Beijing, People’s Republic of ChinaCorrespondence[email protected]
View further author information
show allView further author information
Article: 2202278
|
Received 22 Jan 2023, Accepted 07 Apr 2023, Published online: 01 May 2023
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.